← Back to Clinical Trials
Recruiting NCT06796569

NCT06796569 Systemic Immune Inflammatory Index in Systemic Lupus Erythematosus

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06796569
Status Recruiting
Phase
Sponsor Sohag University
Condition Systemic Lupus Erythematosus
Study Type OBSERVATIONAL
Enrollment 90 participants
Start Date 2024-12-02
Primary Completion 2025-12

Eligibility & Interventions

Sex All sexes
Min Age 16 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
systemic immune inflammatory index

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 90 participants in total. It began in 2024-12-02 with a primary completion date of 2025-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to investigate the association between the systemic immune-inflammation index and disease activity, as well as lupus nephritis in patients with systemic lupus erythematosus

Eligibility Criteria

Inclusion Criteria: * o Older than 16 years * In a patient with SLE, patients who fulfill the criteria of the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR). * In patients with LN, patients whose diagnosis is confirmed by kidney biopsy and pathohistological verification (WHO classification, and the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification. Exclusion Criteria: * Patients with other autoimmune rheumatological diseases, lymphoproliferative disorders, malignancies, liver diseases, end-stage kidney disease, diabetic nephropathy, active infections, recent history of blood transfusion and patients with deficiencies in vitamin B12, folate, and iron are excluded from the study.

Contact & Investigator

Central Contact

Shorouk Mohamed abdelmageed, master degree

✉ Shrouk011107@med.sohag.edu.eg

📞 02 +01099082079

Frequently Asked Questions

Who can join the NCT06796569 clinical trial?

This trial is open to participants of all sexes, aged 16 Years or older, studying Systemic Lupus Erythematosus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06796569 currently recruiting?

Yes, NCT06796569 is actively recruiting participants. Contact the research team at Shrouk011107@med.sohag.edu.eg for enrollment information.

Where is the NCT06796569 trial being conducted?

This trial is being conducted at Sohag, Egypt.

Who is sponsoring the NCT06796569 clinical trial?

NCT06796569 is sponsored by Sohag University. The trial plans to enroll 90 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology